Shire Pharmaceuticals has received U.S. Food and Drug Administration clearance to market Adderall XR (mixed amphetamine salts), a new once-a-day treatment for attention deficit/hyperactivity disorder (ADHD). Adderall XR, a new formulation of Shire's popular Adderall, provides all-day treatment in one morning dose.
Adderall XR contains immediate-release and delayed-release Microtrol beads in a 50:50 ratio, meaning that 50% of the active ingredient is released immediately and 50% is released at midday.
No comments:
Post a Comment